Bayer Shuffles Atara’s CAR-Ts Out Of Its Cell Therapy Deck

Biotech’s Fortunes Riding On Other Assets

Bayer is handing back rights to two early-stage off-the-shelf CAR-Ts to Atara, but the split could still be good news for the biotech company.

Bayer, Wuppertal
Bayer will now focus on its in-house cell and gene therapy pipeline via subsidiaries AskBio and BlueRock Therapeutics. • Source: Shutterstock

Bayer is walking away from its alliance with Atara Biotherapeutics on two early-stage solid-tumor targeting CAR T-cell therapies, in a move that slims down a packed cell and gene therapy pipeline.

Atara’s shares have dipped on the news, as the deal first signed in 2020 with a $60m upfront payment...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip